CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Recruiting· 20 target
Drug / intervention
Aleetodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06765733
NCT06765733Early Ph 1RecruitingOn TrackUpdated 9mo ago
CompareCT.gov

The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

Beijing Tiantan Hospital·interventional·Posted Jan 9, 2025·Updated Sep 3, 2025

In Brief

A Early Phase 1 clinical trial evaluating Aleeto for Multiple System Atrophy - Parkinsonian Subtype (MSA-P) and Multiple System Atrophy, MSA. Currently recruiting, targeting 20 participants across 1 site.

Detailed Summary

This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
CountriesChina
Collaborators--

Timeline

Early Ph 1Recruiting
202520262027
First PostedJan 9, 2025
Enrollment StartMay 31, 2025
Primary CompletionSep 30, 2026
Study CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 1.5 years agoPrimary completion in 3 months

Interventions

Aleetodrug

"Aleeto" is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection.